AbbVie Inc. (ABBV) Stock Chart

NYSE
$282.93-0.55 (-0.19%)After hours

View the AbbVie Inc. stock chart with market data, key statistics, volume, financial metrics, latest news, and exportable historical data.

Source
Delayed Quote
Quote Time
Oct 14, 2026, 9:06 PM UTC
Delay
20 min source-reported delay

Market data is for research and educational use only, not investment advice. Quotes may be delayed depending on the source and exchange; verify important prices with your broker or data provider.

Read the ABBV trend first

Use the range controls to compare short-term moves with the longer-term AbbVie Inc. stock chart. A move that looks large on 1D can look routine on a 1Y or 5Y chart.

Check price with volume

Volume helps show whether a move happened with broad participation or thin trading. Compare recent bars with the average volume and news context before drawing conclusions.

Verify before acting

This page is built for research and education. Quotes, analyst fields, and news can be delayed or revised, so verify important prices with your broker or primary data provider.

Key Statistics

Previous Close$274.36
Open$277.00
Day Range$275.97 — $285.40
52 Wk Range$190.75 — $285.40
Volume5,585,201
Avg Volume4,855,932
Market Cap500.94B
P/E (TTM)80.08
P/E (Fwd)17.48
EPS (TTM)$3.54
Dividend Yield2.52%
Beta0.23
50 Day Avg$260.08
200 Day Avg$233.14
Shares Out1.77B
PEG Ratio0.56
Price/Book—

Financial Metrics

Revenue
64.39B
Revenue Growth
10.20%
Gross Margin
72.79%
Operating Margin
40.03%
Profit Margin
9.80%
Total Cash
6.57B
Total Debt
70.88B
Free Cash Flow
16.87B
Analyst Target
$282.61
Analyst Consensus
Buy
Analyst Opinions
28

About AbbVie Inc.

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
57,000
Headquarters
North Chicago, IL, United States
Website
abbvie.com
CEO
Mr. Robert A. Michael CPA

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Related Charts

Data Definitions

Previous close

The most recent prior regular-session close reported by the market data source.

Day range

The source-reported high and low for the current or most recent trading session.

Volume

The number of shares, units, contracts, or asset quantity reported as traded during the period.

Moving averages

The 50-day and 200-day averages smooth recent prices to give quick trend context.

Market cap

A company or fund size estimate based on price and shares outstanding when source data is available.

P/E ratio

Price divided by earnings per share. It is most useful when compared with peers and growth expectations.